Idioma:

Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity

Hill, Colin S. ; Rosati, Lauren M. ; Hu, Chen ; Fu, Wei ; Sehgal, Shuchi ; Hacker-Prietz, Amy ; Wolfgang, Christopher L. ; Weiss, Matthew J. ; Burkhart, Richard A. ; Hruban, Ralph H. ; De Jesus-Acosta, Ana ; Le, Dung T. ; Zheng, Lei ; Laheru, Daniel A. ; He, Jin ; Narang, Amol K. ; Herman, Joseph M.

Annals of surgical oncology, 2022-04, Vol.29 (4), p.2456-2468 [Periódico revisado por pares]

Cham: Springer International Publishing

Texto completo disponível

Citações Citado por

Enviar para

Título:
Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity
Autor: Hill, Colin S. ; Rosati, Lauren M. ; Hu, Chen ; Fu, Wei ; Sehgal, Shuchi ; Hacker-Prietz, Amy ; Wolfgang, Christopher L. ; Weiss, Matthew J. ; Burkhart, Richard A. ; Hruban, Ralph H. ; De Jesus-Acosta, Ana ; Le, Dung T. ; Zheng, Lei ; Laheru, Daniel A. ; He, Jin ; Narang, Amol K. ; Herman, Joseph M.
Assuntos: Adenocarcinoma ; Adenocarcinoma - pathology ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Chemotherapy ; Humans ; Medicine ; Medicine & Public Health ; Metastases ; Morbidity ; Multivariate analysis ; Neoadjuvant Therapy ; Oncology ; Pancreatic cancer ; Pancreatic Neoplasms - pathology ; Pancreatic Tumors ; Patients ; Radiation ; Radiation therapy ; Radiosurgery ; Retrospective Studies ; Surgery ; Surgical Oncology ; Survival ; Toxicity
É parte de: Annals of surgical oncology, 2022-04, Vol.29 (4), p.2456-2468
Descrição: Background Patients with borderline resectable pancreatic cancer (BRPC) or locally advanced pancreatic cancer (LAPC) are at high risk of margin-positive resection. Neoadjuvant stereotactic body radiation therapy (SBRT) may help sterilize margins, but its additive benefit beyond neoadjuvant chemotherapy (nCT) is unclear. The authors report long-term outcomes for BRPC/LAPC patients explored after treatment with either nCT alone or nCT followed by five-fraction SBRT (nCT-SBRT). Methods Patients with BRPC or LAPC from 2011 to 2016 who underwent resection after nCT alone or nCT-SBRT were retrospectively reviewed. Baseline characteristics were compared, and the propensity score with inverse probability weighting (IPW) was used to compare pathologic/survival outcomes. Results Of 198 patients, 76 received nCT, and 122 received nCT-SBRT. The nCT-SBRT cohort had a higher proportion of LAPC (53% vs 22%; p < 0.001). The duration of nCT was longer for nCT-SBRT (4.6 vs 2.9 months; p = 0.03), but adjuvant chemotherapy was less frequently administered (53% vs 67.1%; p < 0.001). Adjuvant radiation was administered to 30% of the nCT patients. The nCT-SBRT regimen more frequently achieved negative margins (92% vs 70%; p < 0.001), negative nodes (59% vs 42%; p < 0.001), and pathologic complete response (7% vs 0%; p = 0.02). In the multivariate analysis, nCT-SBRT remained associated with R0 resection ( p < 0.001). The nCT-SBRT cohort experienced no significant difference in median overall survival (OS) (22.1 vs 24.5 months), local progression-free survival (LPFS) (13.5 vs. 15.4 months), or distant metastasis-free survival (DMFS) (11.7 vs 16.3 months) after surgery. After SBRT, 1-year OS was 77.0% and 2-year OS was 50.4%. Perioperative Claven-Dindo grade 3 or greater morbidity did not differ significantly between the nCT and nCT-SBRT cohorts ( p = 0.81). Conclusions Despite having more advanced disease, the nCT-SBRT cohort was still more likely to undergo an R0 resection and experienced similar survival outcomes compared with the nCT alone cohort.
Editor: Cham: Springer International Publishing
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity

Cham: Springer International Publishing

Buscando em bases de dados remotas. Favor aguardar.